Toward Repositioning Niclosamide for Antivirulence Therapy of Pseudomonas aeruginosa Lung Infections: Development of Inhalable Formulations through Nanosuspension Technology

Molecular Pharmaceutics

Volumn 12, Issue 8, 2015, Pages 2604-2617

  Costabile, Gabriella ^a   D'Angelo, Ivana ^b   Rampioni, Giordano ^c   Bondì, Roslen ^c   Pompili, Barbara ^d   Ascenzioni, Fiorentina ^d   Mitidieri, Emma ^a   D'Emmanuele Di Villa Bianca, Roberta ^a   Sorrentino, Raffaella ^a   Miro, Agnese ^a   Quaglia, Fabiana ^a   Imperi, Francesco ^d   Leoni, Livia ^c   Ungaro, Francesca ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

^c ROMA TRE UNIVERSITY   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

antivirulence drugs; cystic fibrosis; nanosuspensions; niclosamide; Pseudomonas aeruginosa; pulmonary delivery; quorum sensing; rat

Indexed keywords

MANNITOL; NANOCRYSTAL; NANOPARTICLE; NICLOSAMIDE; POLYSORBATE 20; POLYSORBATE 80; SODIUM CHLORIDE; ANTIINFECTIVE AGENT; POWDER;

AEROSOL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; CYSTIC FIBROSIS; CYTOTOXICITY; DRUG FORMULATION; DRUG SOLUBILITY; DRUG STABILITY; DRUG STORAGE; DRY POWDER; HYDRODYNAMICS; LUNG FLUID; LUNG INFECTION; LUNG TOXICITY; MALE; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS INFECTION; QUORUM SENSING; RAT; SIMULATION; SPRAY DRYING; TOXICITY TESTING; ZETA POTENTIAL; ANIMAL; CHEMISTRY; DRUG EFFECTS; DRUG REPOSITIONING; INHALATIONAL DRUG ADMINISTRATION; LUNG DISEASES; MEDICINAL CHEMISTRY; MICROBIOLOGY; PATHOGENICITY; PATHOLOGY; POWDER; PRECLINICAL STUDY; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; TRENDS; VIRULENCE; WISTAR RAT;

ADMINISTRATION, INHALATION; ANIMALS; ANTI-BACTERIAL AGENTS; CHEMISTRY, PHARMACEUTICAL; DRUG EVALUATION, PRECLINICAL; DRUG REPOSITIONING; LUNG DISEASES; MALE; NANOPARTICLES; NICLOSAMIDE; POWDERS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RATS; RATS, WISTAR; VIRULENCE;

EID: 84938315671     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/acs.molpharmaceut.5b00098     Document Type: Article

References (48)

1. Horsley, A.; Cunningham, S.; Innes, J. A. Cystic Fibrosis; Oxford University Press: New York, 2010.
2. O'Sullivan, B. P.; Freedman, S. D. Cystic fibrosis Lancet 2009, 373 (9678) 1891-1904
3. Ratjen, F. A. Cystic fibrosis: Pathogenesis and future treatment strategies Respir. Care 2009, 54 (5) 595-605
4. Doring, G.; Worlitzsch, D. Microbiology of CF lung disease. In Cystic Fibrosis; Horsley, A.; Cunningham, S.; Innes, J. A., Eds.; Oxford University Press: New York, 2010; pp 31-44.
5. Rogers, G. B.; Hoffman, L. R.; Doring, G. Novel concepts in evaluating antimicrobial therapy for bacterial lung infections in patients with cystic fibrosis J. Cystic Fibrosis 2011, 10 (6) 387-400
6. Rasko, D. A.; Sperandio, V. Antivirulence strategies to combat bacteria-mediated disease Nat. Rev. Drug Discovery 2010, 9 (2) 117-128
7. Allen, R. C.; Popat, R.; Diggle, S. P.; Brown, S. P. Targeting virulence: Can we make evolution-proof drugs? Nat. Rev. Microbiol. 2014, 12 (4) 300-308
8. Lee, D. G.; Urbach, J. M.; Wu, G.; Liberati, N. T.; Feinbaum, R. L.; Miyata, S.; Diggins, L. T.; He, J.; Saucier, M.; Deziel, E.; Friedman, L.; Li, L.; Grills, G.; Montgomery, K.; Kucherlapati, R.; Rahme, L. G.; Ausubel, F. M. Genomic analysis reveals that Pseudomonas aeruginosa virulence is combinatorial Genome Biol. 2006, 7 (10) R90
9. Williams, P.; Camara, M. Quorum sensing and environmental adaptation in Pseudomonas aeruginosa: A tale of regulatory networks and multifunctional signal molecules Curr. Opin. Microbiol. 2009, 12 (2) 182-191
10. Schuster, M.; Sexton, D. J.; Diggle, S. P.; Greenberg, E. P. Acyl-homoserine lactone quorum sensing: From evolution to application Annu. Rev. Microbiol. 2013, 67, 43-63
11. LaSarre, B.; Federle, M. J. Exploiting quorum sensing to confuse bacterial pathogens Microbiol. Mol. Biol. Rev. 2013, 77 (1) 73-111
12. Rampioni, G.; Leoni, L.; Williams, P. The art of antibacterial warfare: Deception through interference with quorum sensing-mediated communication Bioorg. Chem. 2014, 55, 60-68
13. Imperi, F.; Massai, F.; Ramachandran, P. C.; Longo, F.; Zennaro, E.; Rampioni, G.; Visca, P.; Leoni, L. New life for an old drug: The anthelmintic drug niclosamide inhibits Pseudomonas aeruginosa quorum sensing Antimicrob. Agents Chemother. 2013, 57 (2) 996-1005
14. Heijerman, H.; Westerman, E.; Conway, S.; Touw, D.; Doring, G. Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: A European consensus J. Cystic Fibrosis 2009, 8 (5) 295-315
15. Gaspar, M. C.; Couet, W.; Olivier, J. C.; Pais, A. A.; Sousa, J. J. Pseudomonas aeruginosa infection in cystic fibrosis lung disease and new perspectives of treatment: A review Eur. J. Clin. Microbiol. Infect. Dis. 2013, 32 (10) 1231-1252
16. d'Angelo, I.; Conte, C.; La Rotonda, M. I.; Miro, A.; Quaglia, F.; Ungaro, F. Improving the efficacy of inhaled drugs in cystic fibrosis: Challenges and emerging drug delivery strategies Adv. Drug Delivery Rev. 2014, 75C, 92-111
17. Devarakonda, B.; Hill, R. A.; Liebenberg, W.; Brits, M.; de Villiers, M. M. Comparison of the aqueous solubilization of practically insoluble niclosamide by polyamidoamine (PAMAM) dendrimers and cyclodextrins Int. J. Pharm. 2005, 304 (1-2) 193-209
18. Rabinow, B. E. Nanosuspensions in drug delivery Nat. Rev. Drug Discovery 2004, 3 (9) 785-796
19. Muller, R. H.; Gohla, S.; Keck, C. M. State of the art of nanocrystals-Special features, production, nanotoxicology aspects, and intracellular delivery Eur. J. Pharm. Biopharm. 2011, 78 (1) 1-9
20. Chavhan, S. S.; Petkar, K. C.; Sawant, K. K. Nanosuspensions in drug delivery: Recent advances, patent scenarios, and commercialization aspects Crit Rev. Ther. Drug Carrier Syst. 2011, 28 (5) 447-488
21. Jacobs, C.; Muller, R. H. Production and characterization of a budesonide nanosuspension for pulmonary administration Pharm. Res. 2002, 19 (2) 189-194
22. Chiang, P. C.; Hu, Y.; Blom, J. D.; Thompson, D. C. Evaluating the suitability of using rat models for preclinical efficacy and side effects with inhaled corticosteroids nanosuspension formulations Nanoscale Res. Lett. 2010, 5 (6) 1010-1019
23. Britland, S.; Finter, W.; Chrystyn, H.; Eagland, D.; Abdelrahim, M. E. Droplet aerodynamics, cellular uptake, and efficacy of a nebulizable corticosteroid nanosuspension are superior to a micronized dosage form Biotechnol. Prog. 2012, 28 (5) 1152-1159
24. Daniels, T.; Mills, N.; Whitaker, P. Nebulizer systems for drug delivery in cystic fibrosis Cochrane Database Syst. Rev. 2013, 4, CD007639
25. Marques, M. R. C.; Loebenberg, R.; Almukainzi, M. Simulated biological fluids with possible application in dissolution testing Dissolution Technol. 2011, 18 (3) 15-28
26. Marple, V. A.; Olson, B. A.; Santhanakrishnan, K.; Roberts, D. L.; Mitchell, J. P.; Hudson-Curtis, B. L. Next generation pharmaceutical impactor: A new impactor for pharmaceutical inhaler testing. Part III. Extension of archival calibration to 15 L/min J. Aerosol Med. 2004, 17 (4) 335-343
27. Massai, F.; Imperi, F.; Quattrucci, S.; Zennaro, E.; Visca, P.; Leoni, L. A multitask biosensor for microvolumetric detection of N-3-oxo-dodecanoyl-homoserine lactone quorum sensing signal Biosens. Bioelectron. 2011, 26 (8) 3444-3449
28. Gruenert, D. C.; Willems, M.; Cassiman, J. J.; Frizzell, R. A. Established cell lines used in cystic fibrosis research J. Cystic Fibrosis 2004, 3 (Suppl. 2) 191-196
29. Lanone, S.; Rogerieux, F.; Geys, J.; Dupont, A.; Maillot-Marechal, E.; Boczkowski, J.; Lacroix, G.; Hoet, P. Comparative toxicity of 24 manufactured nanoparticles in human alveolar epithelial and macrophage cell lines Part. Fibre Toxicol. 2009, 6, 14
30. De Stefano, D.; Coletta, C.; Bianca, R.; Falcone, L.; d'Angelo, I.; Ungaro, F.; Quaglia, F.; Carnuccio, R.; Sorrentino, R. A decoy oligonucleotide to NF-kappaB delivered through inhaleable particles prevents LPS-induced rat airway inflammation Am. J. Respir. Cell Mol. Biol. 2013, 49 (2) 288-295
31. d'Emmanuele, D. V.; Mitidieri, E.; Donnarumma, E.; Tramontano, T.; Brancaleone, V.; Cirino, G.; Bucci, M.; Sorrentino, R. Hydrogen sulfide is involved in dexamethasone-induced hypertension in rat Nitric Oxide 2014, 14) 10
32. van Tonder, E. C.; Maleka, T. S.; Liebenberg, W.; Song, M.; Wurster, D. E.; de Villiers, M. M. Preparation and physicochemical properties of niclosamide anhydrate and two monohydrates Int. J. Pharm. 2004, 269 (2) 417-432
33. Cipolla, D.; Gonda, I. Formulation technology to repurpose drugs for inhalation delivery Drug Discovery Today 2011, 8 (3-4) 123-130
34. Law, G. L.; Tisoncik-Go, J.; Korth, M. J.; Katze, M. G. Drug repurposing: A better approach for infectious disease drug discovery? Curr. Opin. Immunol. 2013, 25 (5) 588-592
35. Graul, A. I.; Cruces, E.; Stringer, M. The year's new drugs and biologics, 2014: Part I Drugs Today 2015, 51 (1) 37-87
36. Pilcer, G.; Amighi, K. Formulation strategy and use of excipients in pulmonary drug delivery Int. J. Pharm. 2010, 392 (1-2) 1-19
37. Wang, Y.; Zheng, Y.; Zhang, L.; Wang, Q.; Zhang, D. Stability of nanosuspensions in drug delivery J. Controlled Release 2013, 172 (3) 1126-1141
38. de Villiers, M. M.; Mahlatji, M. D.; Malan, S. F.; van Tonder, E. C.; Liebenberg, W. Physical transformation of niclosamide solvates in pharmaceutical suspensions determined by DSC and TG analysis Pharmazie 2004, 59 (7) 534-540
39. de Villiers, M. M.; Mahlatji, M. D.; van Tonder, E. C.; Malan, S. F.; Lotter, A. P.; Liebenberg, W. Comparison of the physical and chemical stability of niclosamide crystal forms in aqueous versus nonaqueous suspensions Drug Dev. Ind. Pharm. 2004, 30 (6) 581-592
40. Van, E. B.; Van Den Mooter, G.; Augustijns, P. Top-down production of drug nanocrystals: Nanosuspension stabilization, miniaturization, and transformation into solid products Int. J. Pharm. 2008, 364 (1) 64-75
41. Teeranachaideekul, V.; Junyaprasert, V. B.; Souto, E. B.; Muller, R. H. Development of ascorbyl palmitate nanocrystals applying the nanosuspension technology Int. J. Pharm. 2008, 354 (1-2) 227-234
42. Yamasaki, K.; Kwok, P. C.; Fukushige, K.; Prud'homme, R. K.; Chan, H. K. Enhanced dissolution of inhaleable cyclosporine nanomatrix particles with mannitol as matrix former Int. J. Pharm. 2011, 420 (1) 34-42
43. Hecq, J.; Deleers, M.; Fanara, D.; Vranckx, H.; Amighi, K. Preparation and characterization of nanocrystals for solubility and dissolution rate enhancement of nifedipine Int. J. Pharm. 2005, 299 (1-2) 167-177
44. Burness, C. B.; Keating, G. M. Mannitol dry powder for inhalation: In patients with cystic fibrosis Drugs 2012, 72 (10) 1411-1421
45. Yang, Y.; Tsifansky, M. D.; Shin, S.; Lin, Q.; Yeo, Y. Mannitol-guided delivery of Ciprofloxacin in artificial cystic fibrosis mucus model Biotechnol. Bioeng. 2011, 108 (6) 1441-1449
46. Rundfeldt, C.; Steckel, H.; Scherliess, H.; Wyska, E.; Wlaz, P. Inhaleable highly concentrated itraconazole nanosuspension for the treatment of bronchopulmonary aspergillosis Eur. J. Pharm. Biopharm. 2013, 83 (1) 44-53
47. Li, Y.; Li, P. K.; Roberts, M. J.; Arend, R. C.; Samant, R. S.; Buchsbaum, D. J. Multi-targeted therapy of cancer by niclosamide: A new application for an old drug Cancer Lett. 2014, 349 (1) 8-14
48. Andrews, P.; Thyssen, J.; Lorke, D. The biology and toxicology of molluscicides, Bayluscide Pharmacol. Ther. 1982, 19 (2) 245-295